New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
14:03 EDTADHDAlcobra submits INDA with FDA for Phase III trial
Alcobra announced the submission of an Investigational New Drug Application with the U.S. FDA to initiate a Phase III clinical trial with MG01CI. "With the submission of this IND, the company has achieved an additional major milestone in its development program of MG01CI for ADHD and other cognitive disorders. Given the positive results in our two previous Phase II studies in adults with ADHD we look forward to working closely with the FDA to meet the remaining requirements necessary to bring this therapy to the market," said Dr. Yaron Daniely, president & CEO of Alcobra.
News For ADHD From The Last 14 Days
Check below for free stories on ADHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
11:03 EDTADHDOptions with increasing implied volatility
Options with increasing implied volatility: ADHD VNET AVNO RAX VALE NLY EWZ BBBY SYY GGP
September 10, 2014
11:23 EDTADHDOptions with increasing implied volatility
Subscribe for More Information
September 9, 2014
12:08 EDTADHDOptions with increasing implied volatility
Subscribe for More Information
September 8, 2014
10:17 EDTADHDAlcobra October volatility elevated into Phase III trial data
Alcobra September call option implied volatility is at 170, October is a t 289, December is at 203; compared to its 13-week average of 187 according to Track Data, suggesting large October price movement into Phase III trial data of MDX in adult ADHD subjects.
09:33 EDTADHDAlcobra Phase III data could be major stock mover, says FBR Capital
Subscribe for More Information
September 4, 2014
08:40 EDTADHDAlcobra should be bought ahead of data, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use